The short version of HGF/c-Met fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-17. Anything still debated is marked as such rather than presented as settled.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
=== Critical reviews === "You Hurled Me Into the Depths, Into the Very Heart of the Seas" received mostly positive reviews from critics. Matt Schimkowitz of The A.V. Club gave the episode an "A–" grade and wrote, "Not to be hyperbolic, but tonight's Righteous Gemstones was the funniest 36 minutes in television history. Okay, I won't go that far, but it was a series high. There wasn't a single punchline that didn't hit, a costume choice (or lack thereof) that wasn't a godsend, or a needle drop that was out of place. “You Hurled Me Into the Depths, Into the Very Heart Of The Seas” launches the final season's story out of the deep and finds the production confidently and hilariously ascending toward that big disco ball in the sky." Scott Tobias of Vulture gave the episode a 4 star rating out of 5 and wrote, "As lowbrow laughs go, there's nothing funnier than full-frontal male nudity, and there's certainly no funnier moment than Baby Billy dropping his drawers in front of the Gemstones in the dressing room after their rehearsal goes awry. “Behold, look at this.
=== Muscle involvement === Diagnosing MCTD involves identification of inflammatory myopathy that is histologically and clinically identical to polymyositis (PM). The majority of persons with MCTD do not experience clinical weakness. People with MCTD typically have mild myositis, with normal muscle enzymes and electromyographic results. Some people may be completely asymptomatic. Myositis can be severe and difficult to differentiate from conventional dermatomyositis. Myalgia is a prevalent complaint among patients with MCTD.
=== Size preferences among sexual partners === In a 1994 cover story by Psychology Today, 1,500 readers (about two-thirds women) were surveyed about male body image. Many of the women were not particularly concerned with penis size, and over 71% thought men overemphasized the importance of penis size and shape. Generally, the women polled cared more about width than men thought, and less about length than men thought, although the strength of preference for either among women showed a similar pattern. A small study of 50 undergraduate women, surveyed by two popular male athletes on campus about their perceptions of sexual satisfaction; found the width of a penis feels better than the length of a penis, when subjects are asked to choose between the two (size was left unspecified). It was also concluded that this may show that penis size overall affects sexual satisfaction, since women chose between the two options they were given. A 2002 study at Groningen University Hospital, asked 375 sexually active women (who had recently given birth) the importance of penis size. The results showed that 21% of women thought length was important and 32% thought that girth was important. A 2013 study conducted at the Australian National University, showed that penis size influences a man's sex appeal, and the taller the man, the bigger the effect. The study showed life-sized 3D computer-generated images, altering the height and other physical attributes, with women typically registering preferences in under 3 seconds. A preference for taller men's larger penis size was indicated.
The three substrates of this enzyme are L-2-aminoadipate 6-semialdehyde (L-allysine), oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are (S)-α-aminoadipic acid, reduced NADH, and a proton. This enzyme can also use nicotinamide adenine dinucleotide phosphate as its cofactor. The enzyme participates in lysine biosynthesis and biodegradation.
Research suggests that during reproduction, fungal spores from X. parietina may engage in a form of reproductive parasitism (a type of symbiosis where a microorganism alters the reproduction of a host) by "stealing" algal partners from Physcia lichens, which contain the same algal species. This algal sharing strategy provides a reproductive advantage, as germinating X. parietina fungal spores can bypass the uncertain process of finding compatible free-living algae. However, the species engages in a long-term ecological succession pattern. Studies tracking lichen communities over five-year periods found that Physcia species (such as P. adscendens and P. caesia) are comparatively short-lived, typically developing and vanishing within about two years, while X. parietina populations persisted throughout. Eventually, in sheltered or humid locations, bryophytes (particularly Orthotrichum species) tend to invade and overgrow lichen-covered surfaces—representing the normal succession pattern in canopy situations. The regenerative capacity of X. parietina allows it to maintain its presence longer than many other lichen species during this successional process, but it is eventually replaced by vigorously growing mosses in most sheltered habitats.
Sources: en.wikipedia.org
Ubenimex (INN), also known more commonly as bestatin, is a competitive, reversible protease inhibitor. It is an inhibitor of arginyl aminopeptidase (aminopeptidase B), leukotriene A4 hydrolase (a zinc metalloprotease that displays both epoxide hydrolase and aminopeptidase activities), alanyl aminopeptidase (aminopeptidase M/N), leucyl/cystinyl aminopeptidase (oxytocinase/vasopressinase), and membrane dipeptidase (leukotriene D4 hydrolase). It is being studied for use in the treatment of acute myelocytic leukemia and lymphedema. It is derived from Streptomyces olivoreticuli. Ubenimex has been found to inhibit the enzymatic degradation of oxytocin, vasopressin, enkephalins, and various other peptides and compounds.
B cells make antibodies that can bind to pathogens, block pathogen invasion, activate the complement system, and enhance pathogen destruction. T cells: CD4+ T helper cells: T cells displaying co-receptor CD4 are known as CD4+ T cells. These cells have T-cell receptors and CD4 molecules that, in combination, bind antigenic peptides presented on major histocompatibility complex (MHC) class II molecules on antigen-presenting cells. Helper T cells make cytokines and perform other functions that help coordinate the immune response. In HIV infection, these T cells are the main index to identify the individual's immune system integrity. CD8+ cytotoxic T cells: T cells displaying co-receptor CD8 are known as CD8+ T cells. These cells bind antigens presented on MHC I complex of virus-infected or tumour cells and kill them. Nearly all nucleated cells display MHC I. γδ T cells possess an alternative T cell receptor (different from the αβ TCR found on conventional CD4+ and CD8+ T cells). Found in tissue more commonly than in blood, γδ T cells share characteristics of helper T cells, cytotoxic T cells, and natural killer cells. Natural killer cells are able to kill cells of the body that do not display MHC class I molecules, or display stress markers such as MHC class I polypeptide–related sequence A (MIC-A). Decreased expression of MHC class I and up-regulation of MIC-A can happen when cells are infected by a virus or become cancerous.
In October 2006, researchers announced that three atoms of oganesson (element 118) had been identified at Joint Institute for Nuclear Research in Dubna, Russia, from bombarding 249Cf with calcium-48, making it the heaviest element ever made. The target contained about 10 mg of 249Cf deposited on a titanium foil of 32 cm2 area. Californium has also been used to produce other transuranic elements; for example, lawrencium was first synthesized in 1961 by bombarding californium with boron nuclei.
=== Natural Metalloenzymes repurposing === In addition to anchoring artificial metal center in the protein scaffold, researchers like Frances Arnold and Yang Yang focused on changing the native environment of natural metallocofactors. Due to the large sequence space that can be evolved in natural metalloenzymes, they can be evolved to catalyse non-native transformations. This process is known as enzyme repurposing. Directed evolution is commonly used to tailor the catalytic capacity and repurpose the enzyme function. Mostly based on native porphyrin-metallocofactor, Arnold's lab has developed many ArMs catalysing regioselective and/or enantioselective transformations, such as Carbon-Boron bond formation, carbene insertion, and aminohydroxylation by evolving the sequence context of the corresponding ArMs. As the pioneers of metalloredox radical biocatalysis, Yang et al. repurposed cytochrome P450s to catalyze atom transfer radical cyclization (ATRC), and Huang et al. repurposed non-heme Fe-dependent enzymes to catalyze an abiological radical-relay azidation and radical fluorination.
(2026) report fossil evidence from the Pyvykha Mountain site (Ukraine) indicative of coexistence of archaeocetes of at least two different body size categories in the same locality during the middle Eocene, and interpret the studied cetaceans as likely to be close relatives of the ancestors of Neoceti. Van Rompaey et al. (2026) describe fossil material of Brevirostrodelphis aff. dividum and Brevirostrodelphis sp. from the Berchem Formation (Belgium), providing evidence of presence of members of this genus in the North Sea Basin and their trans-Atlantic distribution during the Miocene, and reinterpret the type specimen of Phocaenopsis sheynensis as a specimen of Kentriodon sp. The first porpoise fossil material from the western North Atlantic is reported from the Pliocene strata near Charleston (South Carolina, United States) by Kofranek et al. (2026). Tanaka et al. (2026) report the first discovery of fossil material of a toothed whale from the Miocene (Burdigalian to Langhian) strata of the Korematsu Formation (Japan). Buchholtz et al. (2026) report evidence of links between sternal shape and feeding behaviors in extant baleen whales, and reconstruct the transition from raptorial predation to filter feeding during the evolutionary history of baleen whales on the basis of the study of sternal morphology in extinct members of the group. Strauch & Pyenson (2026) report the discovery of fossil material of cf. Salishicetus from the Oligocene or Miocene strata of the Vaqueros Formation (California, United States).
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.